ID: ALA3342214
Max Phase: Preclinical
Molecular Formula: C37H42N2O18S
Molecular Weight: 834.81
Molecule Type: Small molecule
Associated Items:
ID: ALA3342214
Max Phase: Preclinical
Molecular Formula: C37H42N2O18S
Molecular Weight: 834.81
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COC(=O)[C@]12OC[C@]34[C@H]([C@@H](O)[C@@H]1O)[C@@]1(C)CC(=O)C(O)=C(C)[C@@H]1C[C@H]3OC(=O)[C@H](OC(=O)CCC(=O)OCCCCOc1no[n+]([O-])c1S(=O)(=O)c1ccccc1)[C@@H]24
Standard InChI: InChI=1S/C37H42N2O18S/c1-18-20-15-22-36-17-54-37(34(47)51-3,30(45)26(44)28(36)35(20,2)16-21(40)25(18)43)29(36)27(33(46)55-22)56-24(42)12-11-23(41)52-13-7-8-14-53-31-32(39(48)57-38-31)58(49,50)19-9-5-4-6-10-19/h4-6,9-10,20,22,26-30,43-45H,7-8,11-17H2,1-3H3/t20-,22+,26+,27+,28+,29+,30-,35-,36+,37+/m0/s1
Standard InChI Key: CXNPIRVDHAZWTI-QKAUTLGHSA-N
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 834.81 | Molecular Weight (Monoisotopic): 834.2153 | AlogP: 0.19 | #Rotatable Bonds: 13 |
Polar Surface Area: 288.53 | Molecular Species: NEUTRAL | HBA: 19 | HBD: 3 |
#RO5 Violations: 2 | HBA (Lipinski): 20 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 8.64 | CX Basic pKa: | CX LogP: -1.73 | CX LogD: -1.75 |
Aromatic Rings: 2 | Heavy Atoms: 58 | QED Weighted: 0.11 | Np Likeness Score: 1.78 |
1. Tang W, Xie J, Xu S, Lv H, Lin M, Yuan S, Bai J, Hou Q, Yu S.. (2014) Novel nitric oxide-releasing derivatives of brusatol as anti-inflammatory agents: design, synthesis, biological evaluation, and nitric oxide release studies., 57 (18): [PMID:25179783] [10.1021/jm5007534] |
Source(1):